Pfizer Announces Positive Top-Line Results from the First Phase 3 Trial of Investigational Tofacitinib in Adults with Psoriatic Arthritis
Go back to Pfizer Announces Positive Top-Line Results from the First Phase 3 Trial of Investigational Tofacitinib in Adults with Psoriatic Arthritis| Pfizer Inc. (NYSE: PFE) | Delayed: 27.57 -0.08 (0.29%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $27.65 | 52 Week High | $37.39 | |||
| Open | $27.80 | 52 Week Low | $28.25 | |||
| Day High | $27.85 | P/E | 16.71 | |||
| Day Low | $27.42 | EPS | $1.65 | |||
| Volume | 12,139,374 | |||||
